Welcome, Safe Harbor, Agenda John Borgeson , Chief Financial Officer Victor Perlroth, M.D., Chief Executive Officer Key Messages, What to Expect Today Victor Perlroth, MD Chief Executive Officer Tarcocimab and KSI-501: Retinal Vascular Diseases Charles Wykoff, MD, PhD KSI-101: Macular Edema Secondary to Inflammation Summary, Q&A, Closing Kodiak Management Team and Industry Leaders Sumit Sharma, MD Commercial opportunity Victor Perlroth, MD Chief Executive Officer What is MESI? What causes MESI? What is the unmet need? How can this unmet need be addressed? Phase 1b APEX Study – DME and MESI cohorts How does KSI-101 fit into the emerging treatment landscape? PEAK and PINNACLE: KSI-101 pivotal program Charles Wykoff, MD, PhD A patient’s MESI journey Dolly S. Chang, MD, PhD Chief Scientific Officer 8